U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C24H23NO5S
Molecular Weight 437.508
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ALEGLITAZAR

SMILES

CO[C@@H](CC1=CC=C(OCCC2=C(C)OC(=N2)C3=CC=CC=C3)C4=C1SC=C4)C(O)=O

InChI

InChIKey=DAYKLWSKQJBGCS-NRFANRHFSA-N
InChI=1S/C24H23NO5S/c1-15-19(25-23(30-15)16-6-4-3-5-7-16)10-12-29-20-9-8-17(14-21(28-2)24(26)27)22-18(20)11-13-31-22/h3-9,11,13,21H,10,12,14H2,1-2H3,(H,26,27)/t21-/m0/s1

HIDE SMILES / InChI
Molecular Formula C24H23NO5S
Molecular Weight 437.508
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Aleglitazar is a dual agonist of PPARalpha/PPARgamma which was developed by Hoffmann-La Roche for the treatment of type 2 diabetes. Aleglitazar activates PPAR receptors with EC50 in nanomolar range and exerts a cardioprotective effect in vitro. The drug is currently in phase III of clinical trials.

Originator

Hoffman-La Roche
134
Curator's Comment: # Hoffmann-La Roche Ltd

Approval Year

Unknown
139594
Targets

Targets

Primary TargetPharmacologyConditionPotency
Agonist
2678
 5.0 nM [EC50]
Agonist
2678
 9.0 nM [EC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Phase III
656
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
16.8 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/20336066/
300 μg 1 times / day steady-state, oral
dose: 300 μg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ALEGLITAZAR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
28.9 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/20336066/
600 μg 1 times / day steady-state, oral
dose: 600 μg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ALEGLITAZAR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
3.05 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/20336066/
50 μg 1 times / day steady-state, oral
dose: 50 μg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ALEGLITAZAR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
49.2 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/20336066/
900 μg 1 times / day steady-state, oral
dose: 900 μg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ALEGLITAZAR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
1.1 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/20336066/
20 μg 1 times / day steady-state, oral
dose: 20 μg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ALEGLITAZAR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
5.91 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/20336066/
100 mg 1 times / day steady-state, oral
dose: 100 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ALEGLITAZAR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
141 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/20336066/
300 μg 1 times / day steady-state, oral
dose: 300 μg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ALEGLITAZAR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
204 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/20336066/
600 μg 1 times / day steady-state, oral
dose: 600 μg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ALEGLITAZAR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
26 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/20336066/
50 μg 1 times / day steady-state, oral
dose: 50 μg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ALEGLITAZAR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
402 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/20336066/
900 μg 1 times / day steady-state, oral
dose: 900 μg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ALEGLITAZAR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
8.66 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/20336066/
20 μg 1 times / day steady-state, oral
dose: 20 μg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ALEGLITAZAR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
41.8 nmol × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/20336066/
100 mg 1 times / day steady-state, oral
dose: 100 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ALEGLITAZAR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
11.9 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/20336066/
300 μg 1 times / day steady-state, oral
dose: 300 μg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ALEGLITAZAR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
13.4 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/20336066/
600 μg 1 times / day steady-state, oral
dose: 600 μg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ALEGLITAZAR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
7.77 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/20336066/
50 μg 1 times / day steady-state, oral
dose: 50 μg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ALEGLITAZAR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
16.4 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/20336066/
900 μg 1 times / day steady-state, oral
dose: 900 μg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ALEGLITAZAR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
6.04 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/20336066/
20 μg 1 times / day steady-state, oral
dose: 20 μg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ALEGLITAZAR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
8.2 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/20336066/
100 mg 1 times / day steady-state, oral
dose: 100 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ALEGLITAZAR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Sourcing

Sourcing

Vendor/AggregatorIDURL
001 Chemical
DY105513
https://www.001chemical.com/chem/search?q=DY105513
1PlusChem LLC
1P00DBLC
https://www.1pchem.com/search?query=1P00DBLC
AK Scientific
3431AH
https://aksci.com/item_detail.php?cat=3431AH
AstaTech
42161
http://astatechinc.com/CPSResult.php?CRNO=42161
BOC Sciences
475479-34-6
http://www.bocsci.com/description.asp?cas=475479-34-6
Chem Scene
CS-0008995
http://www.chemscene.com/goproductList/searchProductList?productObj=CS-0008995
Chem Scene
CS-1134
http://www.chemscene.com/goproductList/searchProductList?productObj=CS-1134
Matrix Scientific
125215
http://www.matrixscientific.com/125215.html
MedChem Express
HY-14728
https://www.medchemexpress.com/search.html?q=HY-14728&ft=&fa=&fp=
MolPort
MolPort-035-683-372
https://www.molport.com/shop/molecule-link/MolPort-035-683-372
MolPort
MolPort-047-114-045
https://www.molport.com/shop/molecule-link/MolPort-047-114-045
Molcore
MC105513
http://www.molcore.com/CatMC105513.html
Molnova
M14583
https://www.molnova.com/en/serch-list.html?keywords=M14583
MuseChem
I003657
https://www.musechem.com/product/I003657.html
ShangHai Biochempartner
BCP11370
http://www.biochempartner.com/search_BCP11370
Synthonix
14579
https://synthonix.com/catalogsearch/result/?q=14579
Tetrahedron
TS88924
http://www.thsci.com/search.do?q=TS88924
eMolecules
45475563
https://orderbb.emolecules.com/search/#?query=45475563
mcule
MCULE-7615393654
https://mcule.com/MCULE-7615393654/
PubMed

PubMed

TitleDatePubMed
PPAR-alpha and PPAR-gamma agonists for type 2 diabetes.
2009 Jul 11
A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease.
2009 Jul 20
Pharmacokinetics, pharmacodynamics, and tolerability of aleglitazar in patients with type 2 diabetes: results from a randomized, placebo-controlled clinical study.
2010 Aug
Neuropathy, retinopathy, and glucose-lowering treatments.
2010 Jun
Gateways to clinical trials.
2010 Nov
Patents

Patents

06642389
1
JP2007506800A
1

Sample Use Guides

In Vivo Use Guide
Patients receive 150 mcg orally daily.
Route of Administration: Oral
In Vitro Use Guide
Aleglitazar increased cell viability and reduced apoptosis in human cardiomyocytes at concentrations of 150-600 nM.
Substance Class Chemical
Created
by admin
on Sat Dec 16 16:22:46 GMT 2023
Edited
by admin
on Sat Dec 16 16:22:46 GMT 2023
Record UNII
41T4OAG59U
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ALEGLITAZAR
INN   MI   USAN   WHO-DD  
USAN   INN  
Official Name English
aleglitazar [INN]
Common Name English
ALEGLITAZAR [USAN]
Common Name English
Aleglitazar [WHO-DD]
Common Name English
R1439
Code English
R-1439
Code English
(2S)-2-Methoxy-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-benzothiophen-7-yl}propionic acid
Systematic Name English
ALEGLITAZAR [MI]
Common Name English
RO0728804
Code English
RO-0728804
Code English
BENZO(B)THIOPHENE-7-PROPANOIC ACID, .ALPHA.-METHOXY-4-(2-(5-METHYL-2-PHENYL-4-OXAZOLYL)ETHOXY)-, (.ALPHA.S)-
Common Name English
(S)-2-METHOXY-3-(4-(2-(5-METHYL-2-PHENYLOXAZOL-4-YL-ETHOXY)BENZO(B)THIOPHEN-7-YL)PROPIONIC ACID
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C98233
Created by admin on Sat Dec 16 16:22:46 GMT 2023 , Edited by admin on Sat Dec 16 16:22:46 GMT 2023
Code System Code Type Description
DRUG BANK
DB08915
Created by admin on Sat Dec 16 16:22:46 GMT 2023 , Edited by admin on Sat Dec 16 16:22:46 GMT 2023
PRIMARY
FDA UNII
41T4OAG59U
Created by admin on Sat Dec 16 16:22:46 GMT 2023 , Edited by admin on Sat Dec 16 16:22:46 GMT 2023
PRIMARY
USAN
TT-44
Created by admin on Sat Dec 16 16:22:46 GMT 2023 , Edited by admin on Sat Dec 16 16:22:46 GMT 2023
PRIMARY
ChEMBL
CHEMBL519504
Created by admin on Sat Dec 16 16:22:46 GMT 2023 , Edited by admin on Sat Dec 16 16:22:46 GMT 2023
PRIMARY
WIKIPEDIA
ALEGLITAZAR
Created by admin on Sat Dec 16 16:22:46 GMT 2023 , Edited by admin on Sat Dec 16 16:22:46 GMT 2023
PRIMARY
PUBCHEM
10274777
Created by admin on Sat Dec 16 16:22:46 GMT 2023 , Edited by admin on Sat Dec 16 16:22:46 GMT 2023
PRIMARY
CAS
475479-34-6
Created by admin on Sat Dec 16 16:22:46 GMT 2023 , Edited by admin on Sat Dec 16 16:22:46 GMT 2023
PRIMARY
INN
8736
Created by admin on Sat Dec 16 16:22:46 GMT 2023 , Edited by admin on Sat Dec 16 16:22:46 GMT 2023
PRIMARY
EVMPD
SUB34897
Created by admin on Sat Dec 16 16:22:46 GMT 2023 , Edited by admin on Sat Dec 16 16:22:46 GMT 2023
PRIMARY
NCI_THESAURUS
C72687
Created by admin on Sat Dec 16 16:22:46 GMT 2023 , Edited by admin on Sat Dec 16 16:22:46 GMT 2023
PRIMARY
EPA CompTox
DTXSID70197193
Created by admin on Sat Dec 16 16:22:46 GMT 2023 , Edited by admin on Sat Dec 16 16:22:46 GMT 2023
PRIMARY
MERCK INDEX
m1491
Created by admin on Sat Dec 16 16:22:46 GMT 2023 , Edited by admin on Sat Dec 16 16:22:46 GMT 2023
PRIMARY Merck Index
SMS_ID
100000128143
Created by admin on Sat Dec 16 16:22:46 GMT 2023 , Edited by admin on Sat Dec 16 16:22:46 GMT 2023
PRIMARY
MESH
C542437
Created by admin on Sat Dec 16 16:22:46 GMT 2023 , Edited by admin on Sat Dec 16 16:22:46 GMT 2023
PRIMARY
Related Record Type Details
PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA
TARGET -> AGONIST
PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA
TARGET -> AGONIST
Related Record Type Details
Structure of ALEGLITAZAR
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966